Disease course of clinically isolated optic neuritis

• Verfasst von: Küchlin, Sebastian [VerfasserIn]
• Verfasst von: Ihorst, Gabriele [VerfasserIn]
• Verfasst von: Heinrich, Sven P. [VerfasserIn]
• Verfasst von: Márquez Neila, Pablo [VerfasserIn]
• Verfasst von: Albrecht, Philipp [VerfasserIn]
• Verfasst von: Hug, Martin J. [VerfasserIn]
• Verfasst von: Diem, Ricarda [VerfasserIn]
• Verfasst von: Lagrèze, Wolf A. [VerfasserIn]
• Titel: Disease course of clinically isolated optic neuritis
• Verf.angabe: Sebastian Küchlin, MD, Gabriele Ihorst, PhD, Sven P. Heinrich, PhD, Pablo Márquez Neila, PhD, Philipp Albrecht, MD, Martin J. Hug, PhD, Ricarda Diem, MD, and Wolf A. Lagrèze, MD
• E-Jahr: 2024
• Jahr: May 2024
• Umfang: 8 S.
• Illustrationen: Illustrationen
• Fussnoten: Online veröffentlicht am 8. April 2024 ; Gesehen am 18.03.2025
• Titel Quelle: Enthalten in: Neurology: Neuroimmunology & Neuroinflammation ; official journal of the American Academy of Neurology
• Ort Quelle: Philadelphia, Pa. : Wolters Kluwer, 2014
• Jahr Quelle: 2024
• Band/Heft Quelle: 11(2024), 3 vom: Mai, Artikel-ID e200223, Seite 1-8
• ISSN Quelle: 2332-7812
• DOI: doi:10.1212/NXI.0000000000200223
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1919989374

Abstract

Background and Objectives - Optic neuritis is the most common optic neuropathy in young adults and a frequent manifestation of multiple sclerosis. Its clinical course is pertinent to the design of visual pathway neuroprotection trials. - Methods - This is a secondary analysis of longitudinal data from the TONE trial, which included 103 patients from 12 German academic tertiary centers with acute unilateral optic neuritis as a clinically isolated syndrome and baseline high-contrast visual acuity <0.5 decimal. Patients were randomized to 1,000 mg methylprednisolone i.v./d plus either erythropoietin (33,000 IU/d) or placebo (saline solution) for 3 days. They were followed up at standardized intervals with a battery of tests including high-contrast visual acuity, low-contrast letter acuity, contrast sensitivity, visual fields, visual evoked potentials, and retinal optical coherence tomography. At 6 months, participants answered a standardized questionnaire on vision-related quality of life (NEI-VFQ 25). We describe the disease course with mixed-effects piecewise linear models and calculate structure-function correlations using Pearson r. Because erythropoietin had no effect on the visual system, we use pooled (treatment-agnostic) data. - Results - Patients experienced initial rapid and then decelerating improvements of visual function with thinning of inner and thickening of outer retinal layers. At 6 months, visual parameters were positively correlated with inner and negatively correlated with outer retinal thickness changes. Peripapillary retinal nerve fiber layer thinning predominantly occurred in sectors without previous swelling. At 6 months, macular ganglion cell and inner plexiform layer thinning was weakly correlated with the P100 peak time (r = −0.11) and moderately correlated with the amplitude of visual evoked potentials (r = 0.35). Only functional outcomes were at least moderately correlated with vision-related quality of life. - Discussion - The longitudinal data from this large study cohort may serve as a reference for the clinical course of acute optic neuritis. The pattern of correlation between visual evoked potentials and inner retinal thinning may argue that the latter is mostly due to ganglion cell loss, rather than dysfunction. Visual pathway neuroprotection trials with functional outcomes are needed to confirm that candidate drugs will benefit patients' vision-related quality of life. - Trial Registration Information - ClinicalTrials.gov, NCT01962571.